<SEC-DOCUMENT>0000950170-24-133076.txt : 20241204
<SEC-HEADER>0000950170-24-133076.hdr.sgml : 20241204
<ACCEPTANCE-DATETIME>20241204070508
ACCESSION NUMBER:		0000950170-24-133076
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20241204
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241204
DATE AS OF CHANGE:		20241204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EyePoint Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		241524792

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida Corp.
		DATE OF NAME CHANGE:	20080619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eypt-20241204.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-12-03T18:40:33.1622+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:eypt="http://eyepointpharma.com/20241204">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_cbe82b54-4ce8-456e-9d49-9e8c90fcaa9a" name="dei:EntityCentralIndexKey" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0">0001314102</ix:nonNumeric><ix:nonNumeric id="F_6adb133f-99aa-4865-aad4-f06cc7b8e985" name="dei:AmendmentFlag" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eypt-20241204.xsd"/></ix:references><ix:resources><xbrli:context id="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-04</xbrli:startDate><xbrli:endDate>2024-12-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61637210-b555-4882-a1fb-9c6c26504976" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_0e61768f-c6de-4df8-8a9f-cd2e92ff38ab" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 04, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d22e51d7-fa62-4f0e-9cac-948b6b6e941d" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">EyePoint Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_79e6e44a-7593-45bf-a910-204dbea421bc" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_37a10f4a-1a8c-4db1-ab1f-12851421ffe9" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">000-51122</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f427630b-ef37-4a4c-99af-714ab54d26a1" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">26-2774444</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b104a870-5f73-43ea-bf86-7be5c16c0f7f" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">480 Pleasant Street</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b205199e-8be2-49e5-b386-bdfee8b7ab71" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_62f3b48b-4041-4b9b-896d-455c7641a3e8" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4fd96b5b-7d9d-45bf-9521-e6c893b77b12" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02472</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_7e359bdb-4116-4ea7-a54c-11a30b7d0e7a" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(617)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_6a896f9d-cbef-47c2-8057-928d6f406410" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">926-5000</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42a142f8-2dca-4d1c-b936-5d649e07067f" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28c14d55-9931-4346-9096-7a2785ce8eba" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d79c4202-9890-4529-bdbf-b46fb30b5a84" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7721b7c-59eb-491e-bd1e-59be78229454" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_38323126-5688-4ba8-aec2-d9a290231621" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.001</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_40d7c7ee-12e6-4608-8240-5d66cc2d4292" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">EYPT</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_25d4e6ae-7c31-47e3-8308-72868cb8afec" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_dbe98904-a655-45d1-a133-ca77b7cf7a07" contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 4, 2024, EyePoint Pharmaceuticals, Inc. issued a press release announcing the first patient dosed in the Phase 3 LUCIA clinical trial of DURAVYU</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, formerly EYP-1901, for the treatment of wet age-related macular degeneration ("wet AMD"). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.94%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89.06%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="eypt-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release of EyePoint Pharmaceuticals, Inc. dated December 4, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EYEPOINT PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 4, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ George O. Elston</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">George O. Elston<br/>Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>eypt-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img96707757_0.jpg" alt="img96707757_0.jpg" style="width:229px;height:47px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">                                                                                                                                                                     </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> for the Treatment of Wet Age-Related Macular Degeneration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x2013; Topline data for Phase 3 pivotal program anticipated in 2026 &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">WATERTOWN, Mass., December 4, 2024 (GLOBE NEWSWIRE) &#x2013; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the LUCIA trial, the Company&#x2019;s second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). DURAVYU is an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E&#153; for sustained intraocular delivery.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Dosing the first patient in our second global Phase 3 clinical trial, the LUCIA trial, marks another significant milestone demonstrating our continued focus on execution at EyePoint,&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. &#x201c;We are encouraged by the robust physician and patient interest in DURAVYU with enrollment in our first pivotal trial, the LUGANO trial, exceeding our expectations. With two simultaneous Phase 3 clinical trials underway, the most robust clinical dataset of all long-acting treatments in development for wet AMD, and a strong balance sheet, we are well-positioned as the leader in sustained-release ocular drug delivery bringing impactful therapies to patients suffering from serious retinal diseases.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;We are pleased to have dosed the first patient in the LUCIA trial so soon after dosing the first patient in the LUGANO trial. This underscores our commitment to develop innovative therapies with the potential to change the current treatment paradigm in wet AMD,&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">said Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer of EyePoint. &#x201c;The Phase 3 pivotal program is the first and only sustained release wet AMD pivotal program evaluating re-dosing in both trials. Following a typical non-inferiority approval pathway, the LUGANO and LUCIA trials will provide data on the efficacy, durability, safety and dosing flexibility of treatment with DURAVYU and have the potential to provide the retina community valuable insights on how DURAVYU could be used in &#x2018;real-world&#x2019; practice. With over 240 global sites already committed across both Phase 3 trials and exceptional patient and investigator enthusiasm, we are confident we can rapidly enroll patients in the Phase 3 pivotal trials.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Patients with wet AMD typically require life-long treatment with frequent intravitreal injections to preserve their vision.  This high treatment burden often results in under-treatment and irreversible vision loss,&#x201d; said Adam Gerstenblith, M.D., principal investigator in the LUCIA clinical trial and vitreoretinal surgeon at Mid Atlantic Retina Specialists. &#x201c;The Phase 3 LUCIA trial is an important step forward in our pursuit of more durable treatments that are safe and effective. Moreover, the design of the LUCIA trial includes both treatment na&iuml;ve and previously treated wet AMD patients, as well as re-dosing of DURAVYU every six months, which aligns well with how we would approach potential treatment using DURAVYU in clinical practice. We are proud to be the site to treat a patient with DURAVYU in the LUCIA trial and we look forward to continuing to work with EyePoint to rapidly enroll patients in this critical Phase 3 program.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LUGANO and LUCIA are global, randomized, double-masked, aflibercept controlled, non-inferiority Phase 3 trials assessing the efficacy and safety of DURAVYU in patients with active wet AMD including treatment na&iuml;ve and treatment experienced patients. Each trial is expected to enroll approximately 400 patients globally who will be randomly assigned to a 2.7mg dose of DURAVYU or an on-label</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img96707757_0.jpg" alt="img96707757_0.jpg" style="width:229px;height:47px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">aflibercept control. The LUGANO and LUCIA trials are the only sustained release wet AMD pivotal Phase 3 trials evaluating re-dosing in both trials. Patients in the DURAVYU treatment arm will receive an intravitreal injection of DURAVYU every six months, starting at month two of the trial. DURAVYU is delivered via a standard intravitreal injection in the physician's office, similar to current standard practice with FDA approved anti-VEGF treatments. The primary endpoint of the Phase 3 pivotal trials is the average change in best corrected visual acuity (BCVA) at weeks 52 and 56 versus baseline. Secondary endpoints include safety, reduction in treatment burden, percentage of eyes free of supplemental aflibercept injections and anatomical results as measured by optical coherence tomography (OCT). More information about the trial is available at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">clinicaltrials.gov</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (LUGANO identifier: NCT06668064; LUCIA identifier: NCT06683742).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">About Wet AMD</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss and irreversible blindness in people over the age of 50. Wet AMD is an advanced form of condition that develops when abnormal blood vessels grow into the macular retina, leaking blood or fluid, and leading to potentially severe vision loss. Wet AMD is a lifelong disease that requires continuous treatment so that patients may maintain visual function. Although multiple treatments are now available, challenges still exist as the current standard-of-care is dosed on average every two months in the United States under a treat-and-extend protocol, and these large molecule anti-VEGF treatments only target one pathology of the disease. This lifetime of frequent treatment represents a tremendous burden for patients, physicians, and the health care system, potentially leading to patient noncompliance and further vision loss.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">About DURAVYU</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#153;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DURAVYU</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, f/k/a EYP-1901, is being developed as a potential paradigm-altering treatment for patients suffering from VEGF-mediated retinal diseases. DURAVYU delivers vorolanib, a potent, selective and patent-protected tyrosine kinase inhibitor (TKI) as a solid bioerodible insert using EyePoint&#x2019;s proprietary sustained-release Durasert E</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#153;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> technology. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor inhibitor, inhibiting all VEGF receptors. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection and may have antifibrotic benefits as it also blocks PDGF. DURAVYU is shipped and stored at ambient temperature and is administered with a standard intravitreal injection in the physician's office. DURAVYU is immediately bioavailable with zero-order kinetics release for at least six months.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Positive data from both the Phase 1 DAVIO and Phase 2 DAVIO 2 clinical trials of DURAVYU in wet AMD demonstrated clinically meaningful efficacy data with stable visual acuity and CST and a favorable safety profile. Further, data from DAVIO 2 demonstrated an impressive treatment burden reduction of approximately 88% at eight months, six months after treatment with DURAVYU, with over 80% of patients supplement-free or receiving only one supplemental anti-VEGF injection through up to eight months, six months after treatment with DURAVYU. The data from the DAVIO 2 clinical trial supported the advancement of the wet AMD program and the initiation of the global Phase 3 clinical trials, LUGANO and LUCIA.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DURAVYU is also currently being studied in the Phase 2 VERONA trial for diabetic macular edema (DME). Full topline data is expected in the first quarter of 2025.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">About EyePoint Pharmaceuticals</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#153;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> technology for</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img96707757_0.jpg" alt="img96707757_0.jpg" style="width:229px;height:47px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">sustained intraocular drug delivery. The Company&#x2019;s lead product candidate, DURAVYU</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#153;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#153;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#153;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to potentially improve outcomes in serious retinal diseases. The proven Durasert</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DURAVYU&#153; has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Forward Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding the timing and clinical development and potential of DURAVYU in wet AMD and DME, including our expectations regarding the pace of enrollment for the LUGANO trial and the LUCIA trial for wet AMD, and our beliefs and expectations regarding the anticipated announcement of full topline data from the VERONA trial in the first quarter of 2025; the belief that the interim results from the VERONA trial support DURAVYU&#x2019;s potential to advance to non-inferiority pivotal trials in DME; our beliefs and expectations regarding the anticipated full results from the VERONA trial; the potential for DURAVYU 2.7mg to extend treatment intervals while improving vision; the potential for DURAVYU to provide an immediate benefit over aflibercept control in both BCVA and CST; our optimism that that DURAVYU has the potential to shift the treatment paradigm in wet AMD and DME and improve patient outcomes; our expectations regarding clinical development of our other product candidates, including EYP-2301; our business strategies and objectives; and other statements identified by words such as &#x201c;will,&#x201d; &#x201c;potential,&#x201d; &#x201c;could,&#x201d; &#x201c;can,&#x201d; &#x201c;believe,&#x201d; &#x201c;intends,&#x201d; &#x201c;continue,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;estimates,&#x201d; &#x201c;may,&#x201d; other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint&#x2019;s actual results to be materially different than those expressed in or implied by EyePoint&#x2019;s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the company&#x2019;s clinical development activities; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the company&#x2019;s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img96707757_0.jpg" alt="img96707757_0.jpg" style="width:229px;height:47px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">company&#x2019;s product candidates; changes in the regulatory environment; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the company&#x2019;s ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney&#x2019;s Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the company&#x2019;s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investors:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Christina Tartaglia<br>Precision AQ (formerly Stern IR)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Direct: 212-698-8700</font><font style="color:#ff0000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">christina.tartaglia@sternir.com</font></font><font style="color:#ff0000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Media Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amy Phillips</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Green Room Communications</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Direct: 412-327-9499</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">aphillips@greenroompr.com</font></font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img96707757_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96707757_0.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M"/""D[-4=.&B0],DPF.#):/QXL/C9)341"88_]H # ,!  (1 Q$ /P"?P
M
M
M
M
M
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M/*1=?.Z@OA4DCQU;+[^W6-Q0K4U[Z$H\J1T2HUH:9PDEPIH]?'D.H
M
M
M
M
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MX4<4NK@^ PMQE]Y:Z:U.2BMU:5UUHZYGR,$>,
M
M
M
M
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M.QH159>[EW4_A/'#'>C@N DEME]G:::,%S]]Z7UWJZF!KY&?/:
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M@S2M)D9&9&($TXMQDL)+6C"--/!ZSZ!\
M
M
M
M
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MA]]EES8O&:YU'<DM75WGQ]1LVG",&.
M
M
M
M
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M)BR6'$K;<0I2%H41D9D8J.47%N,DU)/!I[A&&FG@]9]0^'P
M
M
M
M
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M0=>A6MJTK>XBX5X-J46L&FM::(5.$Z<W3J)J:>#3.VCJ.(
M
M
M
M
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MFG@]8'T^   !OC[,W>9S3MYYI%U)MN5=9IQ S2Z]6^H6O7LKK3MU9/D4O/\
M (AFMQZL><7ZEU2M]$S4D<F,13"4F5!MK]D*.?T7=VB4,V@M#U*HE[F7#WLM
MS4]&K#YIE<+V'E*>"N4M#[[@?L/V"QKPS,L5V)B6-9Y@N0565X9F-'69)BV3
M4<QJ?3WM#<Q&I]7:ULQA2FI$2;$?2M"B/X#\>A^ U\K4:MO5E0KQ<*T)-23T
M--:&GQ$'G"4).$TU-/!H[*.LX@
M
M
M
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M4*DH+4I-=9G?1T'
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MZ=:.N,DXM<:>#,-.$Z<G"HG&:W&L&=P'2<0
M
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M2\Q]85_/3\9E95_GY^&^4]G'C.H
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M-WOEQ[ZX5U42.Q7I@P
M
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ML[OU5;7O:KICS"TH-?9>3QA848K1&/D,?+8):$_2)58Z/<QBGJP6>8O8UQ
M   (8'>X[F3V^,SM>)ND[_S:4U]=^ALG(ZF5UB[4SVEEI-58Q)95Y)V#X391
M^C)I,V+"S;5)+U&F(;IV)LWDWHM-7]RO^3-=RG[F+_ZFNLM&ZS]2?TH] T=D
M,KI](^U='_\ VJ]I8VM*:TVEO->W:?M:]>+[KW5.DU3?-E.K%1YQ+#=0
M              .5IKNTQZP8M*>8]!G1SZH>:5_*29D:V7D'U;>8<Z=%(61I
M47PD/DHQFN;+2CSW5I;WM!V]U%3I2W'RK>:W&M*,T];[:K,S;:K;'TJS)$HZ
M'%\W2+8^1)FMZN6LS/S]"-2F5&:TEXI-1$9EC:UO*GI6F!56>[-W&5-UZ&-2
MQW]V/!+V):GNX,]A'G(R     >=[#UY69Y6>FYY(ES$0LZNT)'532CZJ]EE>
M4O,["=5\)>)H,_,GQZDKMHUI4I>]W49O),[KY/7YT<96LGW<-_A6])=G4^#
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M9+M--LMMLLMH:9:0AIIII"6VVVVTDE#;:$D24(0DB(B(B(B(8W7I>LZ#]@
M
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M/@U2O15Q'
M
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M9#)ZD9.,EC"XNM$J5!IZ)0@L*U9:4UY.G.+C59!F%EGZV
M       ?MMQQEQMYEQ;3K2T.-.MK4VXVXVHE(<;6DR4A:%$1D9&1D9!K/DHQ
MG%QDDXM8-/4UO,RVU9N9%G[-CF72$-6/Q&*ZY=42&K _BH;C3E'T2W.4?\ET
M^B7O@/HOQ7X*]OS>[IZMXK;:'99V_.OLMBW0UR@M<=]QWX\&M;FC5D@/&08
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MW5"#PE4QQ\%:^OBNIB6!@H<A8
M                        !PMQDF.X][/\OW]+1^U^M[)\L6D&M]J]G]+U
M_9_;7V?6]'UD>?R]?+YT]>G4ASA3J5/FXREAO)OD/JC*7M4V<+_>1KO_ &]P
MO^M-'_KPY^C7'T<_@OM'+R=3O7UF/[R-=_[>X7_6FC_UX/1KCZ.?P7VAY.IW
MKZS']Y&N_P#;W"_ZTT?^O!Z-<?1S^"^T/)U.]?69VJ%.A645B=72XL^%)03D
M:9"D-2HLALS,B<8D,+<9=09D?BDS(=3BXOFR34D<6FG@]9]0^'P
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M^Q#A?UYWG^&0?E5;_P!;/^&OCC[M4_I7\%=L?>WMB?L0X7]>=Y_AD'Y56_\
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MG4WOPEICUO:OA3*ZS"U=G=SH^XQQCQ/5UM74-@0P)X@
M      TE^\/Y1*QOM,<CX\-U#+N4V^F<76Z;I-NE%E;GP.SG-1TG_P",N5"J
M7&5I_P#8N+5^#J)GL!253:JW;U1527_QR2Y3+9)%2S*&.XI/_*RM &QI/  +
M GW5?$8E/P VOEGI1SL\RY39DAV4UY_7.GQS6NJ8%9!D^9*4^:+92;!U'E,R
M\LGX>O4BH?I/JN>>TJ7N86L>NYS;?6PZQ#-HIMWL8[BIKLM_X$FH5N8
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M,L9/FU(K5"3U-;T9:GN*6&'MDE&\ZRR%MA<VZPHO1);SW&N!]A\9*9%9$>
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M%X782X "UQ[4GV:O!O\ =DU+\TZ\:N[4?B.]_N9^,RNLR^OUO./E-@0P)X@
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MTZZA/13A&*[Z3**J;/1J;M.Y@^O&<?978WC!;0QYUBI;L:BY&O9+#$4&0H
M   TY]V?N^ZG[:6!,4E?%JME\G,XJI$K7&I53UH@TT!92(S&P=FN0'6Y]5A4
M6>R:&(K:V9UX^TMB*MIMN5,B2[979.ZVCK\^3=/+8/NYX:6^\ACH<L-;U16E
MXXI/*9;EE2_GB\8VZ>E^PN'D[!7/\G>5F_.8NTK;</(C8MUL+-++S,1%SG$1
MJ/&:@G%.1L=P_'8:6:?%\?AFHS1%B,MI6X:G73<?<<=7L%EN5V.46JM,OIQI
MT5O:V]^3UR?"^):,$3BWMJ-K35*A%1AR\+>ZS'@9 [@ /0M:ZDVKN;(FL0U!
MK3/]J96\E*VL:USA^0YM?+0I7E)PJG&ZZRG^EYB_E>GY2Z?"//<W=K9T_*W=
M2G2I;\Y**Z[:1PJ5:=*/.JRC&.^VERFT76?80[K6SX\6PA\6+7#*J4EI7M^S
M,YUO@4B.3IM]/:L:O<M8S-E2$+-2B^3#-)(-)_'Z).,W.W.R]LW%W2G-;D(S
MEV5'F]DQ]3.<NIZ'43? F^SAAV3*"L]V![F4^*4B4]QUI736M!P;/:UN[*2E
M)D273738-;0O(Y^#H\:OX2(8V725LW%X+TAK?4%[,DSSO:"P7?OJ?XG"9)[L
MOW0:)"U5>/Z0S)2([;R6\;V["BK<<6\II41!Y?38HV4AI"2<4:E):-"B)*S7
MU27.GTC[-3]M*M#CIO\ Z7(^QS_+WK<UQQ[6)A+MWLW=SK2,>?.S;AOMN=75
MJ%OR[+7$.FW%"9B(;2\Y.<=U+<9JIF$RPKU'7'$H)A!*-WR>19)S-IM=LW>M
M1HWE)2>Y/&GU.[4=/+N'KI9IE];1"K'%[_<\N!K;LZNSI+"947-=.J+6ND.Q
M+"LLXDB!80);*C0]%F0I3;4F+(:6712%I2I)^!D)%&49Q4X-.#U-:4^J>]--
M8K2CX1R  &Y_M:]Z3D%VZ<AK<+MI%GM_BU8V"EY-IRXL5.3L53+<4N7D6H;B
M<ZI.)W3;ZS>>KE&=/:&IPGFF9+B)S$.VFV.L-H*;K1PHYFEW-1+1+@J)>V6Y
MC[:.C!M=R\7F&54+Z//7<W&Y+?X);_'K78+&GCQR'U#RIU#AV\]&9C7YOKG-
MZ],VJM82C;DPY+9^G8T5[7.=)='DE'+)4>=!D)0_&?0:5%\!GKYF&7W>5W<[
M*]@X7$'@T^PT]U/6FM#1!J]"K;571K+":_;%<![6/&=0      $2WWM#]7CB
M3],^;?,=D6IT6>L+OS,?&))LW\_5\!<I!>%V$N  M">Q5]D[PW_H9FOZ6]@C
M6G;?\4WGAQ_EP*_S?UC5XUR(VU"*F-     *8P;@%I     $Y;W<'NNKV;C-
M;V_=_9'ZNP,%I7G..&6W$PC?S' ::,3LO5$R1)7ZLG(\#@MK?I^BE'(HFUQR
M2W\G(.12G2'LOZ-4>?6$?D)OY:*]S)^[XI/1+>EI]UHB.>Y=Y.7IM%=PWW2W
MGO\ $]WAXR6Z*J(V           !4M=Q[[0[GG^^=RB_3AG(VHV>]06/]G1_
MEQ+(L?J5'S4/%1AB,P>HV ]J7[2G@U^\WJ3YVUPP.U'X=O?[:IXK/%F7U"MY
MM\A:Y#5TKH "#3W3.PES^WKS>WOOS1..:]V5KS<>7EF=0X6PL=PZ_H#ET]5'
MG4^05.92Z=KVB)8QGD-.PI$MI]@D.*]%:U,HNO9C;G(K+):%C?2J4[BC#FON
M')/2\&G''<WTL'HTZR79?G-E1M(4:SE&<5AJ;Y#7E]W&[L7YC,,^N[4G]K1G
M_P PMEOIY_PZGQ3V_;N7=^_@OM#[N-W8OS&89]=VI/[6A^86RWT\_P"'4^*/
MMW+N_?P7VA]W&[L7YC,,^N[4G]K0_,+9;Z>?\.I\4?;N7=^_@OM#[N-W8OS&
M89]=VI/[6A^86RWT\_X=3XH^W<N[]_!?:'W<;NQ?F,PSZ[M2?VM#\PMEOIY_
MPZGQ1]NY=W[^"^T/NXW=B_,9AGUW:D_M:'YA;+?3S_AU/BC[=R[OW\%]HU1\
ME>..V.).Z\TX^;QHH6-;2U_^3GY44E?>5&1PX7Y5XG0YM2>C<T4N?53/:<=R
M2(\KTG5^FIPVU=%I412C+LPM<ULX7]E)RM:F/-;36/-DXO0\'K3,C;UZ=S25
M>B\:<L<-S4\.5'A8]QW':\#PK(=E9SAFN<1B-3\KS_*\=PK&(+\J-!9FY#E5
MO#HJ6(]-F.,Q(;4BRGM(4ZZM#;9'YE&22,QTUZU.VH3N*KPI4X.3>O1%8O1Q
M(XSG&G!SE[6*;?$C=+]W&[L7YC,,^N[4G]K1#_S"V6^GG_#J?%,5]NY=W[^"
M^T/NXW=B_,9AGUW:D_M:'YA;+?3S_AU/BC[=R[OW\%]H?=QN[%^8S#/KNU)_
M:T/S"V6^GG_#J?%'V[EW?OX+[0^[C=V+\QF&?7=J3^UH?F%LM]//^'4^*/MW
M+N_?P7VA]W&[L7YC,,^N[4G]K0_,+9;Z>?\ #J?%'V[EW?OX+[0^[C=V+\QF
M&?7=J3^UH?F%LM]//^'4^*/MW+N_?P7VCWCC%[N5W*H._=17^R,-UOK/",4V
M+A65Y+E-IM#$LF7&I<<R6LM[-NKHL,L+VTL[AV%#649E91H[CWE2Y(929K3X
M<RZ0=G)6%6G;SJ5:TZ<HJ*A):6FEBY))+'6]+WDSIN,\L'1E&#E*;BTE@UK7
M"6%8H,A0 $>7N0]OOE%B7*6O[F?;BBT-_O-W#5Z]Y&\?KR3%J:SD!KSY-BT\
MU<6;)L:>-+N)&.5<*'+A',A2G/DN#+KWTV,9+<F?;.Y]EE7+'LWM"Y1LN?SZ
M55:72GCCO/1BVT\&NZDI+FO1F[&]MY6_H%]BJ6.,9=Z__KRM/0:[L9Y*:GQ[
MA%D_;TE=C+N,,XQE-TBUN=(LQ-I6U++S<LGQ_,FW(6YY^/L[$JX7Y04$>2U(
M8IW"2PV1$A33BQ(*F7753.HY^L[R_P K%8*IW"?-YKC\VGS'H;6#EKX3W2H5
M)7:OE=T.<E[;1JP:]KCAJX3-GMF]MODAE._]<<ZN>5&SK25H/651IKA5Q/C9
M!*RS^Y#6E!C\O%L=GYK>V%E<R;"_K,;GO):*5)DV<JRE.3IAQ%QXD-K#;2;1
M9=2L*F29'+RBKU'4N*^'-\I-OG-122P3:W$DDN:L<6WY+^_H1HRL[-\[GRYU
M2>&'.>.+PZO4PT+'2R2D*Z," !XCR2VDC2VB=I;,)]F/.Q?$;)ZB6^2%,KRB
MP0FHQ1AQ"S)+C<C(Y\5"B\3-*C\#^ 0GI'VHCL9L+FFTO.4:]K:3=+'4Z\_D
MZ">^G6E!/@98/13L?+;[I%R?9)QE*WO+VFJR6.*MX/REPTUJ<:$*C3WT0Q7G
MGI+SLB0Z[(D2'7'GWWG%.O//.J-;KKKJS4MQUQ:C-2C,S,SZF/QMG.=2;J5&
MY5)-MMO%MO2VV]+;>MG[QTZ<*4(TJ45&E%)))8)):$DEH22T)+4?S'$YFZOL
M^;Q;I\ISC0%S+].-ES:LZPIMQ71L\AIX3<3*8#2349KDV>/Q8\E)$DB2W6.F
M9]3(ANA^D/;>-IFE]L#>3PIW:])MD]7E:<5&O%;\ITHPFM&A498[AH)^N/H]
MG?9/E_2580QJV3]$NFM?D:LW*WF]Z-.M*=-Z=,KB"6ID@$;]'YI@ 5X?=AY"
MN\D.=N\,JC3?;,5PB^5J'!?(M+L9O&M;/2:-^5!=21&[!O\ *4V5LV9]3Z6'
M0O B(K9R*T]#RRE!KNY+GRXY:>PL%U#]K?TY[%1V&Z(<IR^I#FYA=T?3+C<;
MJW251*2W)4Z7DJ+\V:Y!ER\                             _2%K;6AQ
MM:FW&U)6VXA1I6A:3)25H4DR4E25%U(R\2,#XTI)QDL8LS>U%LM&80"I[9U*
M<DKF"-:CZ)*UB-^5!36R+P]I;,R)])=/$R6DNAF2<;<4?)OG1]H^P5-M+D+R
MRMZ5;+_@3?P)=Z^!^Y?4?#[2/,18   ,+-_8Z55ED>Z9028^11/5<Z%T3\H5
MY-1I70B/H7G86PLS\.JE*/X>IC(VL^=3YKUHM38V^=QEKM9ONZ$L/W98M=GG
M+B2,5M@T99!B-Q!))*D-QE3H1].JBEP?](;2C^!3Z4*:Z_@)PQF,MN/1KV%3
MW+>#XGH[&OJ$<Z:-DH[:=&N:91&.-["@[BAHQ?EK?Y6*6\ZBC*ECN*HS!86$
M?D,   &0_$K?MSQ:Y-:*Y#49/N2]1;-Q3,I<*.KRN7%#76C!91CRC\[1DQD>
M-.RX#O1:#].2KHI)^)8_-;&&9Y;7R^>JK3E''>;7<OJ/!]0Z;FBKBWG0>J46
MNT^HRW5H+ZHRFAI,GQ^>S:T&1U%;?4EG&\_L]C46\-FPK9\?U$H<]&9"D(<1
MYDD?E474B&J52$Z4Y4ZBPG%M-;S6AHK247&3C+1)/ Y<<#X
M        !'[]YB^RYROZ9]/_ (WL!/.CC\31\S4Y$9K(?6"\"17(#80G  %A
MW[KI]FM??O-[1^:6LA0/29^(H_VT/&F0G:#Z^O-KE9(X%>F#
M        ,!NY/P2P?N&<5\WT-DQPJK+$H/*]0YO(CD\]@NSZ>+*3C]L:DH6^
M=+9HD.UUJTW\=ZLEO$CRO$TM&=V=SNOD&:0OJ>+I>UJ1[Z#UKC6N/"EN8GLL
M+R=E<*M'3'5);ZW>VN$JP-H:RSG3&Q<VU/LS'9^)Y_KS);;$LNQVR02)55>4
MLMR%-8-:#4S)CJ<:\[+[2EL2&5(=:6MM:5'LY;7-"\MX75M)3H5(J46MU/\
M;2M:>AEATZD*L%4IO&$EBF=$'><S=QV,NY4]P#Y2Q,>V#>JA\:-]RZ;$-MIF
MOJ*LPFV0^['Q#;+:/(LXZ<5E3W&+4T=/5II3ZU)==C1DIA>VNSBSW+'4MXXY
ME03E#?DO=0_>PQC[Y+4FS$YO8>FV_.@OEX:8\.^NKN<)9;,/LR669,9YJ1'D
M--OL/L.(=9?9=03C3S+K9J0XTXA1*2I)F2B/J0UT::>#UD#U']1\
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MJ=6;CJFXT5MIE"G'%&I1DGQ,^I^(Q$I2F^=-MRWWI/*VV\7I9]XXGP
M            (EOO:'ZO'$GZ9\V^8[(M3HL]87?F8^,239OY^KX"Y2"\+L)<
M !:X]J3[-7@W^[)J7YIUXU=VH_$=[_<S\9E=9E]?K><?*; A@3Q
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MYNIQIV\%C*3>"2_;4M;>A:3A4J0I0=2HU&"6ELFO]O#W8C6&$5U#LSN 6_\
M>AG;J(MDSH/"[J97:SQ=T^KZ(.;Y=5.0[[/[>,?I>LQ7OU].TZAUI2[2.M+I
MTWM!TDW-:4K;(5Y*AJ\K)8SEX,7HBN%IRU/N7H(I>Y_4FW3LES8=\];XEJ75
MQ?$2E=8:BU7I/%(."Z>USA&K\-K4(1#QG L8IL4I6C0@D>L=?2PX<=Z4X1=7
M'EDIUQ1FI:E*,S.LKF[NKVJZ]W4G5K/=E)R?79'JE6I5ESZLG*6^WB>B#SG
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M,1F#U&P'M2_:4\&OWF]2?.VN&!VH_#M[_;5/%9XLR^H5O-OD+7(:NE=
M        !64>\(_:^\NO]P?_ "PZ6&R&P7X3M/\ R_SJA/LE]64OWO'D:8Q,
M#*&37"G]<KB3^\WH;]*F*#&YSZHNO[:KXDCHNOJM3S<N1ENR-42M
M              -/W>(V0=%IW7>LHKYMRL_S*3>6"$.'U=HL(@H4Y&?;+_\
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M>MQ6/&M#[)^-O29LZMD]O\WV?A'F4+>^J>36]1F_*4?_ (IP.N#U$&   "T
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M_-.O&KNU'XCO?[F?C,KK,OK];SCY38$,">(           #P[DYL.%J/C=R
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M^CG(EFW351O:D<5EF7W5SIW&XQM5H>MIW.*6EIK'<Q4%,6<?KH
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MH/"M<:9[ZIIZOWY:.*,D]9'MH+QTJ*M8/NZFE^"NV^PF3UQ1I#@
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M^0\VE;9Q:1C4H*.$:=?ROE*LZ;6J%;",G##N:BFT^;*,8Z3A^@I<
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MTFVZJ9#3KKVU.YCUI1DGV>;UC [0PYUE&>[&HNLTUVBP7%#$+
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MFVL<<QMTVL-<X:Y0X6O;1X<4O;&%SJP]+H>6IKY>FNNMU>RNJMTL9AKX0<
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M9[17-9/&E"?DX[W-I]SHXVG+JE>YK7](OZD_<I\U<4='9>+ZIM($9,>
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MX\C3&)@90R:X4_KE<2?WF]#?I4Q08W.?5%U_;5?$D=%U]5J>;ER,MV1JB5H
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M[]YB^RYROZ9]/_C>P$\Z./Q-'S-3D1FLA]8+P)%<@-A"<
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MIGW!^-Z\:]](_P")I>9I\C(/GWK!^!$D""!F%
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M'BHPQ&8/4; >U+]I3P:_>;U)\[:X8':C\.WO]M4\5GBS+ZA6\V^0M<AJZ5T
M            %91[PC]K[RZ_W!_\L.EALAL%^$[3_P O\ZH3[)?5E+][QY&F
M,3 RADUPI_7*XD_O-Z&_2IB@QN<^J+K^VJ^)(Z+KZK4\W+D9;LC5$K0
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MGCNK^ULXXUI+G;RTR?4[>")WW:^[&?';M\IJ-G9:]%WIR@1&-3FS;JL2QC6
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M>/(TQB8&4,FN%/ZY7$G]YO0WZ5,4&-SGU1=?VU7Q)'1=?5:GFY<C+=D:HE:
M                   '!Y,A3F-Y A"5+6NCMD(0@C4I:E0)!)2E)$9J4HSZ
M$1>)F/%F:<LMN(Q6,G0J>*S(91*,<UM92:45<4VV]27/1!O'XA']"X
M   !P>1XY3Y73S:&^A-SJV<WY'F5^"D*+Q;D1W"^.Q)87T4VXDR4E1=2$EV1
MVNV@V%V@M]J-E[B=KG%K/G0G'4U[J$XZITYKN9PEC&47@SXUCH9K(VOJBXUC
M<>B]ZD['YSBSI;HD=$O)+JKV*;Y2\C%DPC^4GP2XDO.CPZDG]H.@OITV?Z:-
MG_2+?F6NU=K"/I=ISM,'J\M1QTSMYOVLM,J<GY.IIYLI]$H\WB/)Q>IQ
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MQ1GK#>WEQF%W4O;J7.N*LG*3X7N+>26A+<22*[K59UZLJU1XSD\6>J#RG6
M      $<?WHO[-:A_>;U=\TMFBPNC/\ $4O[:?C0,YL_]??FWRHKQ!?Q-@
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MOA-,1(42.TDDH;;0E"$ET(B(0V<YU).=1N4V\6V\6WOMF*;<GC)XMG)#B?
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M#M1^';W^VJ>*SQ9E]0K>;?(6N0U=*Z             "LH]X1^U]Y=?[@_\
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MM7:PCZ7:<[3!ZO+4<=,[>;]K+3*G)^3J:>;*?1*/-XCR<7J<0
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M'CC5\5J(P;RTI0E;IM,EYC))$9_@(4?.3G-SEK;;ZY#V^<VWK9R0XGP
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M)[J6NGQK7'WN,=Q(EF19CSEZ%6?=+VCX.]ZFYP:-Q$/@6T28 "?I[NWW6_\
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MWOZ3][.B[,OMCHUV?S3'&5?);*<O"=O3YZT)+1+%:$EHT:#QL0XG8
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MSIX_.UJ<>/!\_P#Z,3#9]/FY>X]]**]GV"QS&O9!@
M  (_?O,7V7.5_3/I_P#&]@)YT<?B:/F:G(C-9#ZP7@2*Y ;"$X  L._==/LU
MK[]YO:/S2UD*!Z3/Q%'^VAXTR$[0?7UYM<K)' KTP8
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M87E>/=M:XTWN<#GJ\''?3(_GM_Y"EZ)2?RLUIX(_X\F/ 3[Q11#0
M   (X_O1?V:U#^\WJ[YI;-%A=&?XBE_;3\:!G-G_ *^_-OE17B"_B;  6-_N
MSOV7.*?3/N#\;UXU[Z1_Q-+S-/D9!\^]8/P(D@00,PH
M      1+?>T/U>.)/TSYM\QV1:G19ZPN_,Q\8DFS?S]7P%RD%X782X "T][,
M_P!ESPI^ABL_&]P-8]K_ ,37GGGR(KS-/6%7PS9L(V>
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M33N;9/"-2*P7I%OBVY4I-KGPQ<J$FH3;BZ=2ITRCS>(\6&QIP
M                   ,D>-/"[<W.6\V/JK1Z(!9;CVH<YS_ -6U6<>!*^0H
M;,6JQI$U3C+$.VS*_LHM7#=<6EMAV2;[G\RRZ:>JIF=GE-6C=7N/D/+13PX]
M>&ZHI8M;J6"TLH7]26WE#8/HKO:SGS;_ #%JQHX/!XUU)59+#2N90C5DFM4E
M%8IM&F6[I;C&KFWQW(:NPH[^@LY]+>4EM#D5]K3W%5*=@V=79P);;4J#85\U
MA;+S+B4N-.(-*B(R,A:4)PJ052FU*G))IK2FGI33W4S\K4U)*4=,6<8.9]
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M^AC<'XHKQ ^D?\,R\]3Y68;/O5[\.)8WC7L@P      &#O<-X,ZV[A'&3--
M9^EBMMY"%9'J[.O9BD3M<[.JX<QK&LIC(+HY(KS.6[#M(J5(.952I#*5M.*;
M>;S609W<9!F4+^AIAJG'<G!ZX\>[%[DDGI6@]=E=U+*X5:&K4UOK=7:X2K(W
MOH_9/&W;^P=%[>QY[&-BZSR2=C.35+IFZQ[5$42H]C5S/(ANSHKJ"XU,@3&^
MK4R$^T\V9H61C9NQO;?,;2G>VDN=;U(II^P]YIZ&MQIHL.C6IUZ4:U)XPDL4
M>2CUG8;$^V-W"-@=N7DSCVX,<]ON]=WIQ,7W9KQB03<?.-?OS$N2O96G5HBM
MY9C2UJG4\E9I].4E3*U%'D2$+C^TF04-H<ME:5,(W$>ZIS[V7Q7JDM[3K2/%
MF%E"^MW2EHFM,7O/M/=+1_5&T\!W?K;"-NZMR6OS#7FQ<;K,KQ'(ZQ9JBV=/
M;1TR(ZU-N)1(A38YJ-F3%?0W)B26W&7D(=;6A.LUU:U[*XG:747"XIR<9)[C
M7[:&M#6E:"O:E.=&HZ5183B\&BJ;[CWVAW//]\[E%^G#.1M#L]Z@L?[.C_+B
M6+8_4J/FH>*C#$9@]1L![4OVE/!K]YO4GSMKA@=J/P[>_P!M4\5GBS+ZA6\V
M^0M<AJZ5T             %91[PC]K[RZ_W!_P#+#I8;(;!?A.T_\O\ .J$^
MR7U92_>\>1IC$P,H9-<*?URN)/[S>AOTJ8H,;G/JBZ_MJOB2.BZ^JU/-RY&6
M[(U1*T                      T#]YG %Q\LTUM)AHU-6^/WF!63R4]$L.
MX_8IR"F0XKIXKF-Y).\OP^$<_P"(:$_K'R!T\UR;:B"[FM;U;6;WG2GY6GCP
MR5:KAX#/TH_0AM+&KDN>['U'A.A=4;RFM]5H>1JM<$70I8^&C26-*S?\
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M.T7H\7W-O1C']Z6,WV))=0A&?UO*7WDUJA%+JO3[*)$8K\P@
M         &@;WEF!+E]K/.I$9E3K-7MS3D^>LE((HT1S)EUB'E$I25*2J=8L
MM]$D9]7"/IT(S*=]',DMIH)ZW2J)=;'D1F<A:68+P9<A7"C84G( %AW[KI]F
MM??O-[1^:6LA0/29^(H_VT/&F0G:#Z^O-KE9(X%>F#
M            (?'O;W_EYP@_IGO3\1ZQ%M=%7S][X%+EF2;9OYRKQ1Y60DQ<
MQ+  +0GL5?9.\-_Z&9K^EO8(UIVW_%-YX<?Y<"O\W]8U>-<B-M0BIC0
M      (X_O1?V:U#^\WJ[YI;-%A=&?XBE_;3\:!G-G_K[\V^5%>(+^)L !8W
M^[._9<XI],^X/QO7C7OI'_$TO,T^1D'S[U@_ B2!! S"@
M       !$M][0_5XXD_3/FWS'9%J=%GK"[\S'QB2;-_/U? 7*07A=A+@ +3W
MLS_9<\*?H8K/QO<#6/:_\37GGGR(KS-/6%7PS9L(V>
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MJ2_G34K7SI'NU<;22HIZ*%&$.J\9OQ]/%AN$'SZKY3,'%>XBE[/LD@L0(PH
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MT[7;^UIXUZ"T1N(K!.XMTWBXM_.4],J,GNP<9/HE'F\1X8-F3@
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M\WH;]*F*#&YSZHNO[:KXDCHNOJM3S<N1ENR-42M
M .+O*6MR2EN,=N8K<ZGOJNPI;6$Z75J96VD1Z#.BN$?@;<B*^M!_Q&/+?6=M
MF-E6R^\BIV=>E.G.+U2A.+C*+X'%M'LR^_N\JS"AFEA-T[ZVK0JTYK7&I3DI
MPDN&,DFN(A5[<UU:ZCV?GFL[KSJL,*R>VH%2%(],I\6'*6FNM6D'XE'MZTVI
M377H?IO)\"^ ?C!M;L[=;);37^S5[CZ19752ECAASHQD^9-<%2'-G'@DC]\]
MB=J;/;;9'+MK+##T;,+.G6P3QYDI17/IM]]3GSJ<O?19YV(\2@
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MCQ2]O_D4ECN-HQ.=7/H]C))]W/N5U=?8Q++P:YD#
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M   V ]J7[2G@U^\WJ3YVUPP.U'X=O?[:IXK/%F7U"MYM\A:Y#5TKH
M      *RCWA'[7WEU_N#_P"6'2PV0V"_"=I_Y?YU0GV2^K*7[WCR-,8F!E#)
MKA3^N5Q)_>;T-^E3%!C<Y]477]M5\21T77U6IYN7(RW9&J)6@
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MB<>.H\'/K81AQQ9"<^NO+W?D8^TI+#]YZ^MH749(K%?F#
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M#?2PH3EC2D]49/7!\$GIC[[%>Z6$DR+,53?H59]PWW+WGO=7<X>,@TBZR7
M;"^WKW+^2';@V1)S#3-O%NL)R9^$6RM/Y2Y*?P7/HD)+S4=^0U&<1*HLGK69
M"_8;6&:9#"C\CJ9$93D9R/Y_LYEVT-NJ5XG&M'VE2/MH]N+W8O1O8/2>*]L*
M%]3YM5836J2UK_#@)ZG!SOH<$N:L"GI#V!"T%N2:AAF9J/<]I78Z_)LW"\IQ
M\)SB2N+A^<LOOI449IE^/;.(22W:]CJ1"CLZV)SS)I.?DW7LU_J4TWH]]'VT
M>'%..])D.N\HO+1M\WGTM^.GKK6N3A-R25)6E*T*2M"TDI*DF2DJ2HNJ5)47
M4C29'U(R$0,6?H      =+S_ &/KW5&+V.;[1SK#]<894(-RTRS.\EIL2QNN
M0EMQXSFW=]-@5L;^:96HB6X1F23,O@,=U"WN+JJJ-M"=2L]48IR;ZBQ9SA3G
M4ES*:<IO<2Q?8(M_<7]YKU'KRGR#6/ 6(6VME/)DU;F\LDII,/5.'K4E;#UC
MB%':HBW.Q;R&Z2O07)C1*,E^F^2[%CS,+LS9_HWN[B<;G/7Y*VU^33[N7!)K
M1!;^#<MSN7I)!8Y!5FU4O.YI]ZM;X][EXB$1LO9>?[CSW*]H[2RV[SO86<7$
MF^RO+<CFN3[BZM99I)Q^2^OHE#332$-,,MI0Q&8;0TTA#2$(3<]M;4+.A&VM
M81A;P6$8I8)+]M>ZWI>DEM.G"E!4Z:2@E@DCHX[SD>JZ/TILKD9MG!-(Z?QF
M7EVQ]C7\7'<8HXG1'K2Y'F<D3)TI?1BNIZF"T[+G2W32Q$B,N/.*2A"C+RWM
MY;9?:SO;N2A;TXXR?:WVWH2W6\#KK5:="FZM5X0BL66FO;GX-X+V]^+&"<?,
M1=BW%]#0O)MIYNQ'7&<S_9]W'BEDN1FTZ9O1ZQDHK,"L85\>/5PHZ'#6Z3CB
M]9-H<ZKY_F<[^KBH/1"/>P6I<>ZWNR;W"O;Z[G>W$JTM$=26\MQ=OA,Z1A#Q
M@    $2WWM#]7CB3],^;?,=D6IT6>L+OS,?&))LW\_5\!<I!>%V$N  M">Q5
M]D[PW_H9FOZ6]@C6G;?\4WGAQ_EP*_S?UC5XUR(VU"*F-     *8P;@%I  2
M!/=G?M1L4^AC<'XHKQ ^D?\ #,O/4^5F&S[U>_#B6-XU[(,           !J
MI[N_;;Q?N/\ &*SPV''KZW?.MD6F6Z!S*6IN.F#D[L>/\JX7<35$2F\2V%$K
MVHDSJHD1I;42:9+.(3:Y1LIM%5V>S)5FV[&IA&K'?CN22[Z&.*WUC'=,CEE_
M*QN.<_F9:)+@W^-=M;I6"YAB&4:^RS)<%S>AL\6S'#KVUQC*<;NHKD&WH<@H
MYKU;;U%E#>)+D:;7SHZVG$'\"DF-DZ-6E7I1KT9*5&<4XM:4TUBFN!HG\91G
M%3@\8M8I\!UP=IR  V ]J7[2G@U^\WJ3YVUPP.U'X=O?[:IXK/%F7U"MYM\A
M:Y#5TKH             *RCWA'[7WEU_N#_Y8=+#9#8+\)VG_E_G5"?9+ZLI
M?O>/(TQB8&4,FN%/ZY7$G]YO0WZ5,4&-SGU1=?VU7Q)'1=?5:GFY<C+=D:HE
M:                       !XAR.TO4<@=,YQJRU]!E[(*I;E!9/(\Q4V4U
MQE.QVV)24J=2U%M&6R?)'13L93K?7HLQ">D78RTV_P!C;[9>ZYJG<4FZ4W_I
MUX=U1J;^$9I<[#3*#E'5)E@]%FWM[T:;>9?MA9\Z4+:LE6@O]6WGW%>GO8RI
MM\S'1&HH3UQ1#9R"AM\6O;K&;^"_67N/6MA27-;)3Y9$"TJI;L&?#>21F1.Q
MI3"T*Z&9=2'X[7]C=Y7?5LMOX2I7UO5G3J0>N,X2<91?"I)IG[L99F-EG&76
M^;9;4C6RZZHPJTIQU3IU(J<)+@E%IKC.('D/<                  '$7M%
M4Y-4S:2[A-6%98-&S)C/$?0RZD:'&UD9+9?961*;<29+0LB4DR,AGMF-I\]V
M-SVVVEV:N:EKG-K4Y].I#<W'&2>B<)K&,X23C.+<9)IM'QI-8,UE[<U':ZQM
MB,C=GXS8/+*GMS274E=%.?)MAY")#5BRVDS(R(D/H2:T$71:$?LYT!]/61]-
M&1.+YEKMG:4T[NUQT8:(^D4,6W*A.32:;<J,VJ=1O&G4J=$HN+X#Q\; '$
M              "21VA>SU*VU)Q[E!RMQ:1"U3%=C7&K]37\-R/)V>^TI+\+
M+,QKI*$.LZY;427(<)Q)'?'T<<+Y.\J9\0S_ &@5NG96,L:^J4E[G@7OM]^Y
MX]6C'ZEOU-4]G*=?8#HZN(SVBDG"[O*<DU:IZ)4:,EH=SN3FG_Q_:Q^7Q=&8
M8VVVTVAII"&VFT);;;;22&VVT$24(0A)$E*$I+H1%X$0KX_,IMR;E)MR;TL_
M8'P   -1G?@FQ8':8YBOS'T1VEXMKR$AQPS)*I5ENC6U=!8+H1_'DS93;:?_
M +2R$KV'3EM5:):^=/L4YMF2R=-YE2PWWXK*^KMM\,LAYZ<P]2\>JMBP1B]K
M;IR?:]] ;<ZXKJ7&'XTW-KER4E"VX$J9%6W65[CG1M5O8Q&C_P#$(7SM%G%/
M(\IJW\L/*I803]U4?M5P[[]ZFR:W]U&SM95W[;#!<+>KM\2+7#'<?I,2Q^BQ
M7&JR)28YC-/68_04U>T3$"HI*:$Q6U59"83\5F) @QFVFTEX)0@B&KU2I.K4
ME5J-RJ2;;;UMMXMOC97,I.4G*6F3>+.8' ^
M''VU357]59T5[65]U1W5?-J;FFMH4:RJK:JLHSD.QK+.NF-O1)]?/B/+:>9=
M0MMUM9I41I,R'*$Y4Y*<&XSB\4UH::U-/<:/J;B\5H:(5/=)]VKR6JM\CWEV
M[8+5[C,Q3]MD'&"PL?1O\>>_\66_J#(+F6;&04SO53A4=@^U.BFDT0Y$PG&H
MD>X]F>D6G*$;+:!\VJM"K):'YQ+4_?)8/=2P;<JR_/HM*C?:);D]Q^$MSC75
MP(C6:81F>M\HN<(V%B62X+F6.RUP+_$\PH[/&\DI9S9$I<2UI+B-#LH$@DJ(
M_(ZVE70R/IT,6M1K4;BDJUO.,Z,EBI1:::X&M#)+"<*D5.#3@]36E'5QVG(
M              N#..'ZO&AOH8U=\QZ,:EYCZPK^>GXS*RK_ #\_#?*>SCQG
M4           !#X][>_\O.$'],]Z?B/6(MKHJ^?O? I<LR3;-_.5>*/*R$F+
MF)8 !:$]BK[)WAO_ $,S7]+>P1K3MO\ BF\\./\ +@5_F_K&KQKD1MJ$5,:
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MXYE8QE6LG)Z9VS>-6BF]<J$Y<^"UNE-I+FT6:8AIL;Y
M   '!Y'CE/E=/-H;Z$W.K9S?D>97X*0HO%N1'<+X[$EA?13;B3)25%U(279'
M:[:#87:"WVHV7N)VN<6L^="<=37NH3CJG3FNYG"6,91>#/C6.AFLC:^J+C6-
MQZ+WJ3L?G.+.ENB1T2\DNJO8IOE+R,63"/Y2?!+B2\Z/#J2?V@Z"^G39_IHV
M?](M^9:[5VL(^EVG.TP>KRU''3.WF_:RTRIR?DZFGFRGT2CS>(\G%ZG$
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MAS!U3EC)&7H'GNN,NUZZI)]#,GBQZZV<A!I/J75)J\W3KT+KT*14.E2RDO\
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M6#>C4U[\OOYY?5=2,5*,E@UJ[.X1^/NB?_\ (/\ _I/_ /W*B>?FO_\ L/\
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M@G&&.K'!MMO>Q;PQ>&&+,?>9E=7V"K-*"W%H6._NM]5FRL1P\
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M21)2E*2Z)2E)="))$70B(5R8$_0
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MFE.>99]5FGRDGKGM_M7)XJY45P4J7LP9\>=YD]51+]V/LHY/[O=V@OV1?_\
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M'7VDS^YBX5KRX<):USY)--8--)I8-:UJ.J>87U1.,ZM3!\+7(9SC"'C
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M6FZE64I5'K;;;?5>D\,I2F^=)MRX3G1P.(
M
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MRLZ68Y?5A6L:].-2G4@U*$X32E&<9+0XRBTTUH:9QX\YZ@
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MQ6*DJ;I0DM#ILV[-MMM-H::0AMIM"6VVVTDAMMM!$E"$(21)2A*2Z$1>!$,
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M>YN);B7 CWX> Z0
M
M
M
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M;K;USEPRP7@Q2CB\,7SJ5.<E"&BG'5PO=;X7V%@N$]9'E.H
M
M
M
M
M                      TN=P#MUJS5VYWAH*G:;RU295IGNO*]HFD96M*5
MORLCQ2*TCR)RAPR-4J$DDILE&;C7^EFI$K3/I]_3R\ZE6VWV"HI9MW4[JT@L
M/+[LJU"*_P!=ZYTUHK>VC\KBJN^OZ:?U0K((4.CWI)KR>2IQIV=[-X^CK5&A
M<2;Q]'6A4ZKQ=!=Q/Y'"5&/PXVXTXMIU"VW6UJ;<;<2:'&W$&:5H6A1$I*TJ
M+H9'XD8T"E&49.,DU)/!IZT]YGZ81E&<5.#3@UBFM*:>II[Q^1\.0
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MGSZD^W#T'A
M
M
M
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M8?2A^GCI)Z+)U+K,[5WFSL=*O;52J45'?K+#REN]2?E8J'.>$*D]9F,+@*+
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MA""<HT:5*F^8=W&;(^
M
M
M
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M$W3YL'TN6L:>4UE:[2*&-2QKR2K1P7=2I/1&O33]W3TI8.I"FVD8B"I"[@
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MM?M'MQG53:#:F[JWF:5=<IO1&.+:ITX+"-.G'%\VG!1C'3@M+._#/$;
M
M
M
M
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MO7%?",ZVC0X)4Z+6&-)M8F>@O<UP
M
M
M
M
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M%J->FVWB]9_H'P
M
M
M
M
M            .KY7A&&9Y6G3YQB6,YC4F:E?)F4T57?P"4M/E4M,2UBRV$K4
MDNG4D]1C,UR3)L]MO0\[M+:\M.\KTH58_!G&2[!E\FV@S[9RZ].V>O;NQO?I
M+>M4HST>^IRB\.#$PVSGMK<0<W<?E)UL]AUA(\WGFX-D-S1-HZ]3+T*5V5/Q
MF/Y#,^GD@IZ_ ?4B(BIW//TW=$6=RE566NSN)>ZMJM2DNI3<I45U*:+VV>_5
M=TX;/QC1>;1OK:.J-W1I5F^.JHPKRQX:KX,-)BEE/9DUM+4H\*W5G&/H,B\B
M<IQVAS!23\QF9J54OX,2R-'0NA$GH?C_ !"JLT_1OLW5;^Q<ZOK=?]^C2N/Y
M;MO8+FR?]>.U=!+[?R#+[F6[Z/7K6W\Q7>'7?LG@UWV9]J,+46.;CU]:MEU\
MBKNGR/'UJ^)U+S(@-9*2>KG@?11]$^/P^ @M[^CC:FFW]G9QE]6/_<IUJ78B
MJV[P\/ 6-E_Z[]CJD5]JY%F=&6[Y*K0K+7OS=#<X%IT<)YU-[07*.*I"6,BT
MU9$M)FI<+*\J;2T9'T)"RL<$@+-1EX_%)1?QB.UOTC=)])I0N,FJ)[L:]=8<
M?/M8]C$E-O\ K?Z(*R;J6N?4FGJG;V[QXN9=S77:/B_Z1O*K_P"(:G_K=<_V
M4'1__P E]*?TF5?_ ,BI_L'H_P#^V>ASZ+.O_P"-2_\ [!S5;V>^2\OTES\Q
MTQ5-J<-+K;F19C+F-H+X'$-1<#7$=\WX"]=)_P /0>VV_2%TE5<'7O,FI1QT
MIUKB4DM_"-KS7\)'@N_UQ]$U'&-M8Y]6DEH:H6L8M[S<KQ27'S'U3U"@[,.:
MR#;_ "IWIBU01]#=*@PVVR(T_$69DVJQNL7)7QR274R+P49]/BDE4GL/T:YU
M4P^U,\M:2W?)6]2KOZN?4H[N&]NO<P</S+]>>04D_L?9V\KO<\M=4Z&]KYE*
MXPT8O=U)8Z<5D/B/9TT76*:>S+8NRLL=:7YE1ZQ6/8K62$^4B].0P=7?67D\
MW4_YJ8TKX/'P/K864_H_V'MFIYQF.97<T]4/)4(/@:YE6?6J1?#OUAG?ZY^D
M2[4H9%E>4V4&O;5/+7%2/#%^4HT\?"I26O1O9=8%P*XDZ[-MZGTMC%O-0:5G
M.S4Y^=/+=09&E],;+)=O6Q'4FDC+V=AE)&74BZ]3%M9#T$=$VSS4[/);6M67
MNKGG7+Q6[A7E4A%^#&*W<,2DMI/U']->U"<+[/[RA0>CF6O,M$D]SG6T:<Y+
MPYR>YC@995]=7U,*-6U4&'65T-HF8D"OC,PX45E/7RM1HL9#;##2>O@E*2(A
M:]O;V]I1C;6L(4K>"PC&$5&,5O**227 D4O<W5S>W$[J\J5*MU4>,ISDY3D]
M^4I-MOA;/L'<=
M
M
M
M
M
M
M
M
M
/                 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>eypt-20241204.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-12-03T18:40:33.9432+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://eyepointpharma.com/20241204" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:eypt="http://eyepointpharma.com/20241204" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eypt-20241204.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45271912532768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  04,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EyePoint Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2774444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Pleasant Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-5000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYPT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "C.(1999!YDAD!  #/ P  $P
M %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C
M3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=
M(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B
M63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.Q
MD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[
MV?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D
M@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( *,X
MA%D'04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ HSB$61PATN3O    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ HSB$69E<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "C.(19YSD[,E<$  ":$   &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ HSB$69^@&_"Q @
MX@P   T              ( !FPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "C.(19EXJ[',     3 @  "P              @ %W#P  7W)E;',O+G)E
M;'-02P$"% ,4    " "C.(19.JJBYT !   \ @  #P              @ %@
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ HSB$620>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ HSB$6660>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="eypt-20241204.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="eypt-20241204.htm">eypt-20241204.htm</File>
    <File>eypt-20241204.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "eypt-20241204.htm": {
   "nsprefix": "eypt",
   "nsuri": "http://eyepointpharma.com/20241204",
   "dts": {
    "inline": {
     "local": [
      "eypt-20241204.htm"
     ]
    },
    "schema": {
     "local": [
      "eypt-20241204.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eypt-20241204.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eypt-20241204.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://eyepointpharma.com/20241204/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-133076-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-133076-xbrl.zip
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ME/V#NN@+X>]/0S\?.+-FFX]U.1]"'SN']"Z,?A(E::-"['R(;XIY])*(3Z+
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M<96)S,"GN +_"L9=5I<NZK:\ VWZ8WNJZS85;KO2C.4,9*YI8*K<QFJ61HU
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MKA3DK>)XU8KC!U86SQW2>R[R?V5YN)^3%$4#.96)N"DI'TMO98^$@4B^C:^
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M+R-FR!HE"UJ URJ\'D(1#X@=)@8PJ[3X5$!&)-!?%#.ER@X:,4DO59)T0P
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M=_ZV5 O>1+FZ+O!E?<"3\\#DBI /LAP+J[V61FS*F64OK<HYY?4QLW0QQH:
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M[ES!1P=9Z9+-0&>8S[&JC_UQ$J_.ZL:41&9GK5W"S76.VHD%OH%#1_C8\;6
M5%#GSR)V$[^KK=%<72%;W5;/\9C*W2LZ; ARO=!!"L69XIK10<2 2LOHB?,J
MFK7[\@9E1XRKTA=-EL#\5+O8=Z?=UJHI9K3ITI+6*R^Y=;"\OH2D=;<(N[JU
M0&].U5(;N Z=U@F\=XQ*?,6E^LVE+$''M"^GJ/&E?0IT[;83&FL,^%&3<-!]
MZ[CMZ]["U5A!BUWC,2WEPZ[+9_7YE9M,<^,6WTFCT_I@P>9^?3I4U+J@+MQI
MWT+@TZ3TZ^K9RG5?#)O2_UCR,#FNG7%_Y8X$VIC '>Z (R6171EM8R\P,>9\
MH\-,4]42&^\<;&%O^KI>6[<P< [>AW!"_8G+C6\XJ%0?'*)3*:$<P%&&3G6D
MNDC#;LEZ U@7KMT"4<ST)!SHN.8ZDR 3SK/W_DDPAX.?TK].3#9*(]B,)\UE
MN&NAPZ(M@<'M] Q 56&$=:Z&84KPP[(S_MW%M# 9_MO=C]4"G7#F@JV 2V-C
MJC:@H^-%?=J>#E@U5P*$IS79UE_Q91@;'LML_2&S[ERMOR!&@I^QJ7=W:]>&
M*254%+WVV,=,UE\T\K#I*]A0Z>97J5PT#QU)'>7H0)(_S^7K6(2'/1]1FE1<
M^L2[2;>H;%4LSB33%N:>*Y:*8]9EF%%)=8?ABH(.9T4U%3$2 \5J:A4Q2F..
MB=?AUS)PA=7%A2OI=Z&N]6)"&955ZZB4.]M/U+#.)6]&Q$0(,.FH,^A,<W2>
M&U6U476Y8ZSU$;8K5:9+<_>:5\1NSC3[:FD](0S3*+N.B]$H?_ CK,&7DD2K
M8?K-:I&$AK5X?V4\OG%&)7+!=H4[P>@+ =U=$)V6UNOP<(DBX>^LSF8EL$D#
MM0$Z,D79(#K\OJ*_90&RF#D%3[_0L0[ ;WUHPUG[7.>J(U>#9VI=1!EKPP5Y
M?$TBQ,>5OA5\,QF'6IL9N>%I'\()DFU+:0\,EHBU"ZLW_.\_#8%1IS[];1AD
M\63DZ+".Y@,-%:,833P<49!P;!:%+NJB17]ND<[T&>OU^UBY<%%=^$<DKNM6
MP@4$=J7.S(SYKI68+@99 NIFF]K\$ +,G@< \!3C,YB_K" 65O_I*YELZT(D
M:^":^^4W98FK=EFK+W^%4N&V)_3C6/HV87Z;,+]-F-\FS&]("&!-/ZW;L7T/
MU_5AO1;2J6RNK<D(!)>:U;A-@$VG!1F;,1:4:UG[%3!="5E9)_E3A.YD&ZL=
M'T 5DHPDMC6<]1PK*-B8SWR;S#D5, !(2REI80L;.X4QYX#<H[:S^D($=$[G
M]:S31J0]Z,R^]V1LT:\ID&A_?YV;K+M6D^;J<I))8\:SVL=$Z,AZ$R9T797-
MA08T>5*?"66N*Z=9H,Y]3;2<&QV[LKA-3>!;DH)3CM16L3GO^KU0"SIT7Y@L
M4_ #G;W3<9K:5KGS9>AT*E1799M]!%]4$[(=?7D_5R0OPDPW,8*[>X U8'UU
M7X@*9,J=M27CUX=)X9;#2(HP[2W&4.@&ZMB,^;!J^^,J"Z<@VQ;01@LPY/G6
M]?V6\,J*G3FHIG3SZ][.WAX9,+E162OBP F2 0379JHU>W?I8QTK.0*;6^U8
M9"G]<?VD*(0+VYK=#]B>%+_(7>.6L;I&N7:J9=#:23X;)2//MPWOTUOB>5B]
MD85'7E^P1FD%.CE37QS:"HG1Y\,K;ZP=4F5GX>ZR>\MW#Y+-.*W@;H/15!-@
MJ6]LJ =?<JIKOZ.S%.%H>2!\6&:QW>=H[G-2+@&"S1%S22%WYDB_UK;_W?)*
M.O[V1U\W !*LN$];YEU[;FW/JF:1]E)JWK(?O7[>F6M\KO,9K^$B P?0IU7F
M?@V^HIL@:-.AMX5KS>'/9,$B4!15ZI'!A4,@J1$VGC-,*P1Q]-JR^)P.W;1)
MY[S+UM+@8GGGG%>)X7Y?KD6_9IV_F2K,?JSHWA6*$^,[R#&?(ES@/0"78-U>
MSS3H[-6U1!5%#B/)G<^0-3 P\)&><5?TX=&"O1P*7+>RHTS:4EXHBDP#RY(0
M2@;75#EUXDZ!S#73YIIYTF6 RGE-5#KC*$NSH8-MK4AX)ZA)H" ?- _<=HDA
MOIV$ZV=.Z1QS-@W"?_"-'(7_M.4>SBS;5E*,X ?(*4R6IV/[TRG<,U<,-?A5
MW*G_7P_GD-Q,')_=_2YH<\1.ZH'8V]WK/GKRN/MX?V?G&N=[,OFBLZ%M^0K7
M"P7^Z)6!/_Y)U2&9MCV8%.^^:^@+4^6&W!;P7[Z\KX3%=#>ZA-F8E; GO@\\
M'J1TJ2JL4YU_X1J"&[+@YY9*4\X,#,%#=_UZY,S<[V+U0<4\@(JYO[????+@
MR9.OM/#_#*#)W#/W/RDFDUGL>[Y)D]Q&F&\CS!QA?GJ/_K>Z/_WEZ3W^'_+^
M/U!+ 0(4 Q0    ( *,XA%G21RLAFQ(  ':?   1              "  0
M  !E>7!T+3(P,C0Q,C T+FAT;5!+ 0(4 Q0    ( *,XA%F^9''L9P@  %E=
M   1              "  <H2  !E>7!T+3(P,C0Q,C T+GAS9%!+ 0(4 Q0
M   ( *,XA%GB)2FI,!D  )=W   /              "  6 ;  !E>7!T+65X
>.3E?,2YH=&U02P4&      ,  P"[    O30

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>eypt-20241204_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eypt-20241204.xsd" xlink:type="simple"/>
    <context id="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <startDate>2024-12-04</startDate>
            <endDate>2024-12-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_cbe82b54-4ce8-456e-9d49-9e8c90fcaa9a">0001314102</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_6adb133f-99aa-4865-aad4-f06cc7b8e985">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_61637210-b555-4882-a1fb-9c6c26504976">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_0e61768f-c6de-4df8-8a9f-cd2e92ff38ab">2024-12-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_d22e51d7-fa62-4f0e-9cac-948b6b6e941d">EyePoint Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_79e6e44a-7593-45bf-a910-204dbea421bc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_37a10f4a-1a8c-4db1-ab1f-12851421ffe9">000-51122</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_f427630b-ef37-4a4c-99af-714ab54d26a1">26-2774444</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_b104a870-5f73-43ea-bf86-7be5c16c0f7f">480 Pleasant Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_b205199e-8be2-49e5-b386-bdfee8b7ab71">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_62f3b48b-4041-4b9b-896d-455c7641a3e8">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_4fd96b5b-7d9d-45bf-9521-e6c893b77b12">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_7e359bdb-4116-4ea7-a54c-11a30b7d0e7a">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_6a896f9d-cbef-47c2-8057-928d6f406410">926-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_42a142f8-2dca-4d1c-b936-5d649e07067f">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_28c14d55-9931-4346-9096-7a2785ce8eba">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_d79c4202-9890-4529-bdbf-b46fb30b5a84">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_a7721b7c-59eb-491e-bd1e-59be78229454">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_38323126-5688-4ba8-aec2-d9a290231621">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_40d7c7ee-12e6-4608-8240-5d66cc2d4292">EYPT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_25d4e6ae-7c31-47e3-8308-72868cb8afec">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_57d797f9-c17b-4adc-a68c-9fdfc0f596c0"
      id="F_dbe98904-a655-45d1-a133-ca77b7cf7a07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
